Paul Brunetta is the Chief Medical Officer at Hinge Bio. During his 15-year career at Genentech, he led the development of anti-CD20 therapy in immunology. Later in his career, Dr. Brunetta led autoimmune development at Sana Biotechnology and translational science at Juno Therapeutics. He earned his medical degree from Tufts University School of Medicine.
